

Ana Maria Gonzalez-Angulo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7092940/publications.pdf>

Version: 2024-02-01

20
papers

2,362
citations

623574

14
h-index

839398

18
g-index

55
all docs

55
docs citations

55
times ranked

4828
citing authors

#	ARTICLE	IF	CITATIONS
1	Overview of Resistance to Systemic Therapy in Patients with Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2007, 608, 1-22.	0.8	721
2	Emergence of Constitutively Active Estrogen Receptor- β Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1757-1767.	3.2	529
3	Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. <i>Cancer Research</i> , 2015, 75, 3479-3491.	0.4	375
4	Future of Personalized Medicine in Oncology: A Systems Biology Approach. <i>Journal of Clinical Oncology</i> , 2010, 28, 2777-2783.	0.8	223
5	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , 2019, 21, 78.	2.2	141
6	Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 5572-5581.	0.4	75
7	Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. <i>PLoS ONE</i> , 2015, 10, e0136851.	1.1	54
8	Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3870-3883.	3.2	47
9	Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 93.	2.2	45
10	Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2688-2705.	1.9	24
11	Biologic Markers in Axillary Node-Negative Breast Cancer: Differential Expression in Invasive Ductal Carcinoma Versus Invasive Lobular Carcinoma. <i>Clinical Breast Cancer</i> , 2006, 7, 396-400.	1.1	23
12	EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 58.	3.5	23
13	Downregulation of the Cyclin-Dependent Kinase Inhibitor p27kip1 Might Correlate with Poor Disease-Free and Overall Survival in Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2006, 7, 326-330.	1.1	22
14	The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0152585.	1.1	14
15	Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3243-3252.	3.2	14
16	Using Response to Primary Chemotherapy to Select Postoperative Therapy: Long-Term Results from a Prospective Phase II Trial in Locally Advanced Primary Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, 516-521.	1.1	11
17	Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel. <i>Journal of Cancer</i> , 2016, 7, 947-956.	1.2	9
18	Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 266-270.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Importance of accurate HER2 testing in patients with metastatic breast cancer. Clinical Advances in Hematology and Oncology, 2010, 8, 873-4.	0.3	0
20	The importance of accuracy in HER2 testing. Clinical Advances in Hematology and Oncology, 2012, 10, 529-31.	0.3	0